1. Search Result
Search Result
Isoforms Recommended: IL-5
Results for "

IL5

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Peptides

10

Inhibitory Antibodies

2

Natural
Products

27

Recombinant Proteins

2

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9945A

    Interleukin Related Inflammation/Immunology
    Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab (anti-IL5)
  • HY-19969
    YM-90709
    1 Publications Verification

    Interleukin Related Inflammation/Immunology
    YM-90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R).YM-90709 potently inhibits the binding of [ 125I]-IL-5 to IL-5R on human peripheral eosinophils and eosinophilic HL-60 clone 15 cells with IC50 values of 1.0 and 0.57 μM .
    YM-90709
  • HY-P9949

    Sch 55700

    Interleukin Related Inflammation/Immunology
    Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
    Reslizumab
  • HY-P9945

    SB 240563

    Interleukin Related Cardiovascular Disease Inflammation/Immunology
    Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab
  • HY-N8309

    Interleukin Related Inflammation/Immunology Cancer
    Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC50 of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity .
    Luteolin-4'-O-glucoside
  • HY-RS06770

    Small Interfering RNA (siRNA) Others

    IL5 Human Pre-designed siRNA Set A contains three designed siRNAs for IL5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IL5 Human Pre-designed siRNA Set A
    IL5 Human Pre-designed siRNA Set A
  • HY-RS06771

    Small Interfering RNA (siRNA) Others

    Il5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Il5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il5 Mouse Pre-designed siRNA Set A
    Il5 Mouse Pre-designed siRNA Set A
  • HY-RS06772

    Small Interfering RNA (siRNA) Others

    Il5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Il5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il5 Rat Pre-designed siRNA Set A
    Il5 Rat Pre-designed siRNA Set A
  • HY-RS06773

    Small Interfering RNA (siRNA) Others

    IL5RA Human Pre-designed siRNA Set A contains three designed siRNAs for IL5RA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IL5RA Human Pre-designed siRNA Set A
    IL5RA Human Pre-designed siRNA Set A
  • HY-P990058

    Interleukin Related Inflammation/Immunology
    Varokibart (TEV-53275) is a human IgG4λ antibody targeting IL5 .
    Varokibart
  • HY-110295

    GSNOR Inflammation/Immunology
    SPL-334 is a potent and selective S-Nitrosoglutathione reductase (GSNOR) inhibitor. SPL-334 causes a significant reduction in the production of Th2 cytokines IL-5 and IL-13 and the levels of the chemokine CCL11 (eotaxin-1) in the airways. SPL-334 can be used in research of allergic airway inflammation .
    SPL-334
  • HY-19472

    Others Others
    RWJ-58643 is a β-trypsin and trypsin inhibitor that is being studied for the treatment of allergic inflammatory diseases. It significantly reduces nasal allergy symptoms, eosinophil infiltration, and interleukin-5 (IL-5) levels at low doses (100 mg). However, RWJ-58643 causes late eosinophilia and elevated IL-5 levels at high doses (300 mg and 600 mg). This dose-dependent effect suggests that RWJ-58643 has potential therapeutic value in the treatment of allergic inflammation, but its use requires careful dose control. The mechanism of action of RWJ-58643 involves inhibiting β-trypsin released from mast cells, thereby regulating allergic reactions. The results of this study provide an important reference for the use of RWJ-58643 in the treatment of allergic rhinitis, but also suggest potential risks that need to be noted when using it.
    RWJ-58643
  • HY-17002
    Suplatast (Tosilate)
    1 Publications Verification

    IPD 1151T

    Interleukin Related Inflammation/Immunology
    Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity .
    Suplatast (Tosilate)
  • HY-P1111

    Src Interleukin Related Inflammation/Immunology
    Lyn peptide inhibitor is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor can be used for study of  asthma, allergic, and other eosinophilic disorders .
    Lyn peptide inhibitor
  • HY-P1111A

    Src Interleukin Related Inflammation/Immunology
    Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of  asthma, allergic, and other eosinophilic disorders .
    Lyn peptide inhibitor TFA
  • HY-147660

    LPL Receptor Inflammation/Immunology
    IMMH001, also called SYL930, is an orally active, potent and selective S1P1 (sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research .
    IMMH001
  • HY-N8309R

    Interleukin Related Inflammation/Immunology Cancer
    Luteolin-4'-O-glucoside (Standard) is the analytical standard of Luteolin-4'-O-glucoside. This product is intended for research and analytical applications. Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC50 of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity .
    Luteolin-4'-O-glucoside (Standard)
  • HY-165484

    Interleukin Related Inflammation/Immunology
    AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses .
    AVP-13358
  • HY-P9923A

    MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )

    Interleukin Related Inflammation/Immunology
    Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
    Benralizumab (anti-IL5RA )
  • HY-P9923

    MEDI-563; BIW-8405

    Interleukin Related Apoptosis Inflammation/Immunology Cancer
    Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
    Benralizumab
  • HY-P99371

    AK002; Antolimab

    Apoptosis Inflammation/Immunology
    Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
    Lirentelimab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: